The detected increase of hypertension risk has to be explained according to the notable effectiveness of anti-TNF treatment in RA patients and the short of replacement therapy in cases with serious disease activity adiaphorous to conventional DMARD therapy. This evidence concerns the gene TNF and hypertensive disorder.